PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32186774-0	2020	miR-10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.	Cisplatin	22-31	AKT serine/threonine kinase 1	Homo sapiens	123-126	
32186774-10	2020	Expression of phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt) phosphorylation were also decreased in A549 and H1299 cells compared with CTCs after cisplatin treatment.	Cisplatin	159-168	AKT serine/threonine kinase 1	Homo sapiens	69-72	
32186774-13	2020	In conclusion, miR-10a suppressed the PI3K/Akt pathway to strengthen the resistance of CTCs to cisplatin via targeting PIK3CA, providing a new therapeutic target for lung cancer treatment.	Cisplatin	95-104	AKT serine/threonine kinase 1	Homo sapiens	43-46